Related references
Note: Only part of the references are listed.Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy
Rebecca L. Read et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda L. Broz et al.
CANCER CELL (2014)
CAVATAK-mediated oncolytic immunotherapy in advanced melanoma patients
Robert H. Andtbacka et al.
CANCER RESEARCH (2014)
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans
Simona Bramante et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Intralesional Immunotherapy for Melanoma
Peter Hersey et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Treatment of Metastatic Melanoma with Electrochemotherapy
Luca G. Campana et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Topical pharmacotherapy for skin cancer
Giuseppe Micali et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Christine E. Engeland et al.
MOLECULAR THERAPY (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Trial Watch Oncolytic viruses for cancer therapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2014)
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus
Anna Kanerva et al.
CLINICAL CANCER RESEARCH (2013)
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
Kenneth H. Kim et al.
GYNECOLOGIC ONCOLOGY (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
Ilkka Liikanen et al.
MOLECULAR THERAPY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer
Paul Toomey et al.
PLOS ONE (2013)
Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease
Timothy R. Hercus et al.
BLOOD (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
Viruses as anticancer drugs
Stephen J. Russell et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor based antitumor vaccine
Paola Filipazzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Ta-Chiang Liu et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673) - A trial of the eastern cooperative oncology group
SS Agarwala et al.
CANCER (2004)
Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21
DR Shafren et al.
CLINICAL CANCER RESEARCH (2004)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Perilesional injection cutaneous melanoma of r-GM-CSF in patients with metastases
C Hoeller et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor
M Toda et al.
MOLECULAR THERAPY (2000)
Share Paper
